# Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas

## TL;DR

Researchers created the first semi-immortal Schwann cell lines from cutaneous neurofibromas in NF1 patients to aid in developing therapies.

## Contribution

The first semi-immortal Schwann cell lines derived from NF1-associated cutaneous neurofibromas are established and characterized.

## Key findings

- Short-term Schwann cell cultures from NF1 patients were immortalized using hTERT and mCdk4.
- The cell lines were characterized molecularly, cellularly, and functionally for research use.
- These cell lines provide a new resource for studying and developing therapies for NF1 cutaneous neurofibromas.

## Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant condition in which patients are heterozygous for a disruptive pathogenic variant in the NF1 gene. The most characteristic feature of the condition NF1 is the neurofibroma, a benign, multi-cellular tumor which initiates when a cell of the Schwann cell lineage gains a somatic pathogenic variant of the other NF1 allele. Neurofibromas developing at nerve termini in the skin are termed “cutaneous” neurofibromas (cNFs), while those developing within larger nerves are termed “plexiform.” Most patients develop cNFs beginning in late childhood or early adulthood, continuing throughout life at variable rates. Some patients may develop only a few cNFs, while others suffer from thousands. There are no reliably effective physical or pharmaceutical therapies besides surgical removal. Although these are not life-threatening, they are disfiguring and can interfere with normal life functions. To provide a resource for research, we developed short-term cNF Schwann cell cultures from NF1 patients, from which we subsequently established the first semi-immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes. Here we present molecular, cellular, and functional characterization of these cell lines, which will be of utility for investigating and developing NF1 cNF therapies.